Lupin Overview
- Year Founded
-
1968
- Status
-
Public
- Employees
-
28,137
- Stock Symbol
-
500257
- Investments
-
39
- Share Price
-
$21.06
- (As of Friday Closing)
Lupin General Information
Description
Lupin Ltd is a transnational pharmaceutical company engaged in producing, developing, and marketing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The Company has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and the Anti-TB and Cephalosporins segments. It operates through two segments: Pharmaceuticals, which consists of producing, developing, and marketing pharmaceutical products, and Others, which consists of diagnostic services, Digital healthcare services, and the neuro-rehabilitation business. The Company operates in India, the USA, and other countries, with maximum revenue from the USA.
Contact Information
Website
www.lupin.comCorporate Office
- 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway
- Santacruz (East)
- Mumbai, 400055
- India
Corporate Office
- 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway
- Santacruz (East)
- Mumbai, 400055
- India
Lupin Stock Performance
As of 13-Nov-2026, Lupin’s stock price is $21.06. Its current market cap is $9.6B with 457M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $21.06 | $21.49 | $19.99 - $26.42 | $9.6B | 457M | 47.7K | $1.23 |
Lupin Financials Summary
As of 30-Sep-2026, Lupin has a trailing 12-month revenue of $3.29B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 9,589,876 | 11,098,663 | 10,794,310 | 9,034,209 |
| Revenue | 3,288,981 | 3,110,726 | 2,624,508 | 2,374,360 |
| EBITDA | 991,813 | 942,749 | 615,446 | 440,974 |
| Net Income | 561,498 | 603,510 | 388,095 | 231,257 |
| Total Assets | 4,155,184 | 4,066,113 | 3,414,206 | 2,877,584 |
| Total Debt | 643,453 | 701,219 | 636,873 | 350,359 |
Lupin Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lupin Comparisons
Industry
Financing
Details
Lupin Competitors (45)
One of Lupin’s 45 competitors is Cipla, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cipla | Corporation | Mumbai, India | ||||
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India | ||||
| Ajanta Pharma | Corporation | Mumbai, India | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Jubilant Pharmova | Corporation | Noida, India |
Lupin Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Lupin Patents
Lupin Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260224558-A1 | Methylnaltrexone composition for oral administration | Pending | 04-Feb-2025 | ||
| WO-2026139910-A1 | Oral formulation of pimavanserin | Pending | 24-Dec-2024 | ||
| WO-2026126112-A1 | Liquid compositions of valbenazine for oral administration | Pending | 10-Dec-2024 | ||
| WO-2026038127-A1 | A process for processing micronized active pharmaceutical ingredients | Pending | 13-Aug-2024 | ||
| WO-2026028170-A1 | Pharmaceutical composition of edaravone | Pending | 02-Aug-2024 | A61P21/00 |
Lupin Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lupin Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lupin Investments & Acquisitions (39)
Lupin’s most recent deal was a Secondary Transaction - Private with Multicare Pharmaceuticals Philippines for . The deal was made on 01-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Multicare Pharmaceuticals Philippines | 01-Jul-2026 | Secondary Transaction - Private | Pharmaceuticals | ||
| VISUfarma | 01-Apr-2026 | Merger/Acquisition | Pharmaceuticals | ||
| Boehringer Ingelheim (Anti-Diabetes Trademarks GIBTULIO, GIBTULIO MET and AJADUO) | 13-Dec-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Renascience Pharma | 02-Apr-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Sunsure Solarpark Seven | 09-Jan-2025 | Secondary Transaction - Private | Energy Production |
Lupin ESG
Risk Overview
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Lupin Exits (1)
Lupin’s most recent exit was on 10-Oct-2007 from Kyowa Pharmaceutical. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Kyowa Pharmaceutical | 10-Oct-2007 | Completed |
|
Lupin Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| VISUfarma | Amsterdam, Netherlands | 2016 | |
| Generic Health | Box Hill, Australia | 2004 | |
| Nanomi | Oldenzaal, Netherlands | 2004 | |
| MyDynamics | Cape Town, South Africa | 2001 | |
| Multicare Pharmaceuticals Philippines | Makati City, Philippines | 1998 |
Lupin FAQs
-
When was Lupin founded?
Lupin was founded in 1968.
-
Where is Lupin headquartered?
Lupin is headquartered in Mumbai, India.
-
What is the size of Lupin?
Lupin has 28,137 total employees.
-
What industry is Lupin in?
Lupin’s primary industry is Pharmaceuticals.
-
Is Lupin a private or public company?
Lupin is a Public company.
-
What is Lupin’s stock symbol?
The ticker symbol for Lupin is 500257.
-
What is the current stock price of Lupin?
As of 13-Nov-2026 the stock price of Lupin is $21.06.
-
What is the current market cap of Lupin?
The current market capitalization of Lupin is $9.6B.
-
What is Lupin’s current revenue?
The trailing twelve month revenue for Lupin is $3.29B.
-
Who are Lupin’s competitors?
Cipla, Torrent Pharmaceuticals, Ajanta Pharma, Biocon, and Jubilant Pharmova are some of the 45 competitors of Lupin.
-
What is Lupin’s annual earnings per share (EPS)?
Lupin’s EPS for 12 months was $1.23.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
